IL6 and Hyperkalemia: Administration of recombinant human soluble thrombomodulin with fluid resuscitation increased the survival rate of crush-injured rats by attenuating hemoconcentration, manifested as increased hemoglobin and hematocrit levels, mitigating hyperkalemia, decreasing serum interleukin-6 and lactate levels, and improving acid-base balance and renal function (Mohri et al., 2006).